Definitive Healthcare (NASDAQ:DH) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research lowered shares of Definitive Healthcare (NASDAQ:DH) from a hold rating to a strong sell rating in a research note released on Thursday morning,Zacks.com reports.

Several other equities analysts also recently commented on DH. Wall Street Zen downgraded Definitive Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Morgan Stanley restated an “underperform” rating and set a $3.50 price target on shares of Definitive Healthcare in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, January 21st. Canaccord Genuity Group cut their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a research report on Friday, February 27th. Finally, Stephens reduced their target price on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $3.52.

Definitive Healthcare Price Performance

Shares of NASDAQ DH traded down $0.04 during mid-day trading on Thursday, hitting $1.18. 252,425 shares of the stock traded hands, compared to its average volume of 368,888. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.64 and a quick ratio of 1.64. Definitive Healthcare has a twelve month low of $1.07 and a twelve month high of $4.70. The company has a market cap of $166.80 million, a PE ratio of -0.94 and a beta of 1.66. The firm has a 50 day simple moving average of $2.04 and a two-hundred day simple moving average of $2.79.

Institutional Investors Weigh In On Definitive Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the stock. New York State Common Retirement Fund boosted its stake in Definitive Healthcare by 0.4% during the second quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock worth $2,989,000 after acquiring an additional 3,066 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Definitive Healthcare by 32.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after buying an additional 4,407 shares during the period. State of Alaska Department of Revenue increased its position in Definitive Healthcare by 109.3% in the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock valued at $32,000 after buying an additional 5,970 shares in the last quarter. Invesco Ltd. increased its position in Definitive Healthcare by 5.8% in the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock valued at $337,000 after buying an additional 6,400 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Definitive Healthcare during the 2nd quarter worth approximately $32,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.